Rethinking Maintenance Strategies in Metastatic HER2-Positive Breast Cancer

TribeNews
0 Min Read

MedPage Today) — With the DESTINY-Breast09 trial, which was presented at this year’s American Society of Clinical Oncology (ASCO) annual meeting, suggesting a shift in first-line treatment for HER2-positive metastatic breast cancer, questions…

Leave a Comment
Ads Blocker Image Powered by Code Help Pro

Ads Blocker Detected & This Is Prohibited!!!

We have detected that you are using extensions to block ads and you are also not using our official app. Your Account Have been Flagged and reported, pending de-activation & All your earning will be wiped out. Please turn off the software to continue

You cannot copy content of this app